pharmaceutical Articles
-
The Brazilian statutory exemption to pharmaceutical patents: beyond generics
Brazilian patent law offers a statutory exception related specifically to pharmaceutical patents. That exception has a unique importance to the new aspects of the intellectual property rights and to the rights to public health. This article will present this statutory exception and analyse the consequences of its application. The text relates to the new international trends that regulate ...
-
A European innovation system in pharmaceuticals?
This paper analyses the emergence and development of a European pharmaceutical system. In particular it reviews and assesses the influence of new institutional and regulatory frameworks on the creation of this pan-European pharmaceutical system. The paper then explores the implications of the formation of this process on our conceptualisation of the more specific "systems of innovation" ...
-
Adaptive strategies in the Indian pharmaceutical industry
Trade liberalisation and proposed changes in the IPR has ushered in new dynamics in the Indian Pharmaceutical industry. Referring to theoretical debate on industrial organisational policies, the pharmaceutical industry is moving towards consolidation and augmentation, thus towards a "new industrial order". The pharmaceutical industry's adaptation to change, as shown in this article, is ...
-
Strategic innovation management of change in the pharmaceutical industry
The pharmaceutical industry is currently preparing for a transition in many countries that gives rise to many unanswered questions regarding innovation strategy and ultimately may threaten the survival of companies in the industry. The cause of this transition is the GATT/WTO agreement that these countries signed in 1995. This agreement has broad implications for intellectual property rights, and ...
-
The Benefits of Partnering with a Contract Manufacturing Organization (CMO) for Generic Pharmaceutical Companies
The generic pharmaceutical industry is fiercely competitive, with each company striving to add new products and expand its portfolio. However, not all companies possess the necessary resources to undertake such endeavours. Some lack the requisite experience in commercial-scale production using the latest technology, while others lack the capacity to ramp up manufacturing. ...
-
Effective patent life in pharmaceuticals
Effective patent life is lost in pharmaceuticals because of the lengthy time periods required for clinical trials and regulatory approval. A 1984 US law restores some of this lost patent time, while also facilitating generic competition when patents expire. This paper examines this law and the effects of other policy developments on market exclusivity times in pharmaceuticals. It also performs ...
-
Strategic alliance: case study in competitive positioning
The case seeks to identify some of the issues encountered in the development and growth of a family–owned firm in the pharmaceutical business in Lima, Peru. Having overcome the initial challenges of its establishment, the company has become a visible and viable competitor in the Peruvian market and is poised to expand in cross border markets by exploring the prospect of a strategic alliance with ...
-
Patents versus patients: reflections on this blatant patent regime
The paper centres on the 'patents versus patients' debate and delves into the challenges facing India's pharmaceutical sector with the advent of the World Trade Organization (WTO)-Trade-Related Aspects of Intellectual Property Rights (TRIPS) product patent regime. Considering the nation's commitments on international soil and the subsequent domestic legislations enacted to fulfil commitments made ...
-
Strategic business leadership through innovation and globalisation: a case study of Ranbaxy Limited
Ranbaxy Laboratories Ltd. (RLL) is the largest pharmaceutical company incorporated in India. It is also amongst the top league globally and is ranked 9th largest generic company worldwide. Ranbaxy is also credited with the tag of true Indian multinational. The company traces its roots to a chemist shop in Delhi. It is one of the first Indian pharmaceutical company to start a joint venture abroad. ...
-
Sustainable use of biodiversity by the pharmaceutical industry?
This paper discusses a key aspect of a sustainable pharmaceutical use of biodiversity: the increased demand of the pharmaceutical industry for biogenetic resources does not result in an increase of the market value of biodiversity. The increasing interest in biogenetic resources by the pharmaceutical industry since the late 1980s has led, among other things, to contracts between large ...
-
The role of Knowledge Management in the pharmaceutical enterprise
In the knowledge intensive pharmaceutical sector, novelty and value are essential for corporate success. This paper discusses the requirements for, and the role of, effective Knowledge Management, as a means for business optimisation and improvement in terms of performance and competitiveness. The various types of knowledge resources are identified and major issues for both explicit/informational ...
-
Choosing a CDMO: 7 Key Factors to Keep in Mind
The pharmaceutical industry is a highly dynamic industry. It is constantly innovating new and complex drugs with great efficacy. This poses a challenge for generic companies to keep up and develop drugs that match the same level of complexity and effectiveness within a reasonable timeframe and budget. To address this challenge, generic companies often outsource their drug ...
-
Characterization of interaction between tricyclic structures containing pharmaceuticals, their models and humic substances
Their persistence and wide consumption identify pharmaceuticals as “emerging pollutants”. The complexation of pharmaceuticals containing adamantine ring structures and their model substances with humic acids (HA) of different origins was compared using fluorescence spectroscopy as a function of pH, humic acid concentration, ionic strength, and molecular mass of HA. Binding constants between the ...
-
Demographic projections of future pharmaceutical consumption in the Netherlands
Over the next few decades, many Western European countries will undergo a large demographic transformation introduced by the retirement of the "baby boomers" and the possibility of striking increases in longevity. The aim of this study was to estimate the effect of a growing and ageing Dutch population on the future consumption of pharmaceuticals, so as to be able to anticipate the potential ...
-
Knowledge-based industry after market liberalisation: the case of the local pharmaceutical industry in Central and Eastern Europe
Research of the strategic aspects of the generic pharmaceutical industry in Central and Eastern Europe (CEE) suggests that generic pharmaceutical companies have neglected technological innovation capability, market orientation and performance and have underestimated the process of globalisation. This has resulted in deteriorated performance and lost competitiveness. A recommended approach to ...
-
Global pharmaceutical industry: intellectual wealth and asset protection
This is a commentary on the recent trends in the protection of intellectual assets in the Global Pharmaceutical Industry. Patenting inventions, enforcing acquired rights, evolving newer ways of sharing knowledge for effective cooperative working through diverse licensing arrangements between organisations are the keys to success in this fiercely competitive industry.Keywords: intellectual assets, ...
-
The formation of subsequent inter-firm R&D partnerships between large pharmaceutical companies and small, entrepreneurial biotechnology firms – how important is inter-organisational trust?
This paper analyses the role of inter-organisational trust in pharmaceutical biotechnology, an industry characterised by a strong dual market structure. Our main finding is that repeated ties in pairs of large pharmaceutical companies and small, entrepreneurial biotechnology firms, which indicate inter-organisational trust, have a negative effect on subsequent partnering. An explanation for this ...
-
Intellectual property management practices at small and medium-sized enterprises
Small and medium-sized enterprises (SME) contribute to innovation and economic growth, despite their resource shortages and lack of professional intellectual property (IP) management practices. Drawing on social practice theory and combining insights from recent scholarship on IP strategies and its management, this paper examines the cases of three pharmaceutical SME providing insights into how ...
-
Technology strategy revealed: patterns and influences of patent-licensing behaviour in Japanese firms
Patterns of patent in-licensing and out-licensing are examined among Japanese firms in the pharmaceuticals and electronics industries. Sixty-five questionnaires and 24 interview-based cases provide insights into what influences the decisions to "make-or-buy" (in-license) knowledge assets and to "exploit-or-sell" (out-license) R&D outputs. Firm size and resources, the existing portfolio of ...
-
The changing role of technology suppliers in the pharmaceutical industry: the case of drug delivery companies
In this paper, preliminary results of a research project on strategies of drug delivery companies (DDC) are presented to discuss the changing role of technology suppliers in the pharmaceutical industry. Changes in the pharmaceutical industry are presented briefly and related to developments in the drug delivery industry. The early observations are contrasted with existing views from the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you